Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment for sickle cell disease (SCD), being successful in around 85-90% of patients. Mortality and long-term morbidity (including infertility, gonadal failure, and chronic graft-vs.-host disease) associated with conventional approaches curtail the number of patients who undergo allo-HSCT. Recently, it has been demonstrated that cord blood is as effective as and possibly safer than bone marrow in pediatric patients with SCD. Likewise, transplant strategies based on the use of reduced-intensity regimens and the induction of mixed chimerism have been explored to decrease allo-HSCT short- and long-term complications.

Original languageEnglish
Pages (from-to)372-376
Number of pages5
JournalPediatric Blood and Cancer
Volume59
Issue number2
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Hematopoietic Stem Cell Transplantation
Sickle Cell Anemia
Transplants
Chimerism
Fetal Blood
Infertility
Bone Marrow
Pediatrics
Morbidity
Mortality
Therapeutics

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Cord blood transplantation
  • Mixed chimerism
  • Sickle cell disease

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease. / Locatelli, Franco; Pagliara, Daria.

In: Pediatric Blood and Cancer, Vol. 59, No. 2, 08.2012, p. 372-376.

Research output: Contribution to journalArticle

@article{2d280a63896f414c88c22d195973f51c,
title = "Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment for sickle cell disease (SCD), being successful in around 85-90{\%} of patients. Mortality and long-term morbidity (including infertility, gonadal failure, and chronic graft-vs.-host disease) associated with conventional approaches curtail the number of patients who undergo allo-HSCT. Recently, it has been demonstrated that cord blood is as effective as and possibly safer than bone marrow in pediatric patients with SCD. Likewise, transplant strategies based on the use of reduced-intensity regimens and the induction of mixed chimerism have been explored to decrease allo-HSCT short- and long-term complications.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Cord blood transplantation, Mixed chimerism, Sickle cell disease",
author = "Franco Locatelli and Daria Pagliara",
year = "2012",
month = "8",
doi = "10.1002/pbc.24177",
language = "English",
volume = "59",
pages = "372--376",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease

AU - Locatelli, Franco

AU - Pagliara, Daria

PY - 2012/8

Y1 - 2012/8

N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment for sickle cell disease (SCD), being successful in around 85-90% of patients. Mortality and long-term morbidity (including infertility, gonadal failure, and chronic graft-vs.-host disease) associated with conventional approaches curtail the number of patients who undergo allo-HSCT. Recently, it has been demonstrated that cord blood is as effective as and possibly safer than bone marrow in pediatric patients with SCD. Likewise, transplant strategies based on the use of reduced-intensity regimens and the induction of mixed chimerism have been explored to decrease allo-HSCT short- and long-term complications.

AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment for sickle cell disease (SCD), being successful in around 85-90% of patients. Mortality and long-term morbidity (including infertility, gonadal failure, and chronic graft-vs.-host disease) associated with conventional approaches curtail the number of patients who undergo allo-HSCT. Recently, it has been demonstrated that cord blood is as effective as and possibly safer than bone marrow in pediatric patients with SCD. Likewise, transplant strategies based on the use of reduced-intensity regimens and the induction of mixed chimerism have been explored to decrease allo-HSCT short- and long-term complications.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Cord blood transplantation

KW - Mixed chimerism

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84862268473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862268473&partnerID=8YFLogxK

U2 - 10.1002/pbc.24177

DO - 10.1002/pbc.24177

M3 - Article

C2 - 22544533

AN - SCOPUS:84862268473

VL - 59

SP - 372

EP - 376

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -